DOCSLIB.ORG

3355.Full.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
3355.Full.Pdf [CANCER RESEARCH 44, 3355-3359, August 1984] Enhancement of the Sensitivity of Human Colon Cancer Cells to Growth Inhibition by Acivicin Achieved through Inhibition of Nucleic Acid Precursor Salvage by Dipyridamole1 Paul H. Fischer,2 Rifat Pamukcu, Gerard Bittner, and James K. V. Willson2-3 Department of Human Oncology, University of Wisconsin School of Medicine, Madison, Wisconsin 53792 [P. H. F., R. P., J. K. V. W.J, and William S. Middleton Memorial Veterans Medical Center, Madison, Wisconsin 53705 [G. B., J. K. V. W.] ABSTRACT mammary and lung xenografts (8). Although acivicin inhibits numerous enzyme reactions involving the transfer of nitrogen This study was undertaken to determine if salvage of nucleic from the 7-carboxamide of L-glutamine (10), including L-aspara- acid precursors might constitute a mechanism of resistance to gine synthetase (3), carbamoyl phosphate synthetase II (1, 10), acivicin in human colon cancer cells and, if so, to establish phosphoribosylformylglycinamidine synthetase (10), and amido- whether dipyridamole, an inhibitor of nucleoside and nucleobase phosphoribosyl transferase (4, 10), inhibition of 2 other L-gluta- transport, can block the salvage process and restore sensitivity mine-dependent enzymes, CTP synthetase (4,10,18) and XMP to acivicin. Acivicin inhibited the replication of human colon aminase (10), appears to be most closely associated with the cancer cells (VACO 5) in vitro in a dose- and time-dependent cytotoxicity of acivicin. Depletion of the CTP and GTP pools and fashion. In addition, marked cell lysis was evident after a 24-hr expansion of the DTP pool have typically been seen (10,13, 14, exposure to acivicin at concentrations greater than 1 ng/m\. The 30). primary metabolic effect of acivicin was depletion of the cytidine In rodent cancer cells, perturbation of both purine and pyrimi- triphosphate and guanosine triphosphate pools. Adenosine tri- dine metabolism is evidently critical, since cytosine and guanine phosphate levels were also reduced, but apparently as a con nucleosides antagonize acivicin cytotoxicity much more effec sequence of the guanosine triphosphate depletion. VACO 5 cells tively when they are used in combination than when they are exposed to acivicin (3 /iQ/ml) efficiently salvaged low levels (1 used alone (18,30). These data suggest the potentially important í¿m)ofcytidine, guanosine, and guanine and could, therefore, role which salvage of nucleic acid precursors might play in restore the depleted nucleotide pools. The combination of cyti modifying the actions of acivicin. In particular, studies on rat dine and guanosine, but not either nucleoside alone, provided hepatoma 3924A cells have documented the ability of nucleo significant protection against the growth-inhibitory properties of sides to circumvent the growth-inhibitory effects of acivicin (14, acivicin. Dipyridamole, at a noncytotoxic concentration (5 /¿M), 24,25,30). Furthermore, dipyridamole, an inhibitor of nucleoside blocked repletion of the cytidine triphosphate and guanosine transport (11, 19-21), antagonized the protection afforded by triphosphate pools in cells exposed to acivicin and the nucleic salvage mechanisms and substantially enhanced the cytotoxicity acid precursors. As a result, the growth-inhibitory effects of of acivicin (24, 25, 30). Since the antitumor activity of acivicin in acivicin were maintained. The salvage of cytidine was particularly humans is now being evaluated in Phase II trials, including colon sensitive to inhibition by dipyridamole, and no restoration of cancer, we felt that several important questions regarding the cytidine triphosphate pools was evident. The cellular uptake of actions of this drug in human cells should be addressed. Does a variety of nucleic acid precursors was differentially sensitive to acivicin inhibit the growth of a human colon cancer cell line, such inhibition by dipyridamole. The 50% inhibitory dose values ranged as VACO 5? Are the cytotoxic effects seen at clinically achievable from 0.01 to 2.5 fiM for cytidine and uridine, respectively. The concentrations and times of exposure to acivicin? Does salvage results of this study indicate that, although the replication of of nucleic acid precursors appear to be a likely mechanism of VACO 5 cells was inhibited by acivicin, low levels of nucleosides resistance to acivicin? Does the use of dipyridamole block reple and nucleobases can circumvent the cytotoxicity. Dipyridamole tion of the nucleotide pools and provide a reasonable therapeutic effectively blocked the salvage pathways and restored the sen approach for maintaining the growth-inhibiting properties of aciv sitivity of the cancer cells to the antiproliferative actions of icin? acivicin. MATERIALS AND METHODS INTRODUCTION Acivicin,4 a structural analogue of L-glutamine, is an antitumor Materials. Acivicin (NSC 163501) was obtained from the National Cancer Institute, Investigational Drugs division. Dipyridamole, nucleo- agent isolated from Streptomyces sviceus (6). The compound tides, nucleosides, and nucleobases were purchased from either Sigma has activity against several murine tumors, the L1210 and P388 Chemical Co. (St. Louis, MO) or P-L Biochemicals (Milwaukee, Wl). leukemias (6) and M5076 ovarian carcinoma (8), and human Aldrich Chemical Co. (Milwaukee, Wl) supplied the Alamine (tri-n-octyla- 1 Supported in part by CA 14520 and the Veterans Administration Medical mine) and Freon (1,1,2-trichlorotrifluoromethane). [8-3H]Guanosine (5 Ci/ mmol), [5-3H]cytidine (30 Ci/mmol), and [8-"C]guanine sulfate (51 nCi/ Research Service. Portions of this study have been presented at the Central Society for Clinical Research, November 2,1983, Chicago, IL (28). mmol) were purchased from Amersham/Searie Corp. (Arlington Heights, 2 To whom requests for reprints should be addressed. IL). [5-3H]Uridine (20 Ci/mmol) and [5-3H]deoxycytidine (25 Ci/mmol) 3 Recipient of an American Cancer Society Junior Faculty Clinical Fellowship. 'The abbreviation used is: acivicin, L-(aS,5S)-a-amino-3-chloro-4,5-dihydro-5- were obtained from Moravek Biochemcials, Inc. (Brea, CA). isoxazolacetic acid. Cell Culture. VACO 5 cells, a human colorectal cell line, were grown Received November 14,1983; accepted May 9,1984. in Eagle's minimal essential medium supplemented with 2 mM u-gluta- AUGUST1984 3355 Downloaded from cancerres.aacrjournals.org on September 27, 2021. © 1984 American Association for Cancer Research. P. H. Fischer et al. mine, 0.1 mu nonessential amino acids (Grand Island Biological Co., Grand Island, NY), insulin (2 //g/ml), transferrin (2 ¿jg/ml),and 7.5 nM sodium selenite (Sigma), gentamicin (50 ^g/ml) (Schering Co., Kenilworth, NJ), and 8% heat-inactivated fetal bovine serum, Lot 100374 (Hyclone, O.Ijig/ml Logan, UT). The contributions from the serum yielded final medium concentrations of less than 0.1 /JM guanosine and cytidine and 2.1 ^M guanine. Dissociation medium was identical to growth medium, except that a Ca2*- and Mg2+-free minimal essential medium was used and fetal bovine serum was excluded. VACO 5 cells were established from a poorly differentiated adenocarcmoma of the cecum and characterized as described previously (16). Stock cultures are passaged weekly and have maintained morphological, karyotypic, and drug sensitivity characteristics during the 12-month course of this study. VACO 5 cells were determined to be negative for Mycoplasme contamination, as demonstrated by culture under aerobic and anaerobic conditions (Wisconsin State Labo ratory of Hygiene, Madison, Wl). Cytotoxicity. Exponentially growing cells, initially plated at a density of 2 x 10* cells/ml in 25-sq cm tissue culture flasks, were maintained at 37°in a humidified 5% CO2 atmosphere. Medium containing the various additives was added 12 hr later. In the experiment described in Chart 1, 24 48 72 96 the exposure to acivicin was continued for an additional 2 to 96 hr. The EXPOSURE TO ACIVICIN (hr) cells were then washed twice, fresh medium was added, and the incubation was continued such that the entire growth period was 96 hr. Chart 1. Effects of acivicin on the replication of VACO 5 cells. Exponentially growing cells were plated at a density of 2 x 104 cells/ml and incubated for 12 hr For the experiment shown in Chart 3, the cells were exposed to acivicin, the nucleosides, or dipyridamole for 24 hr. The cells were then washed prior to the addition of acivicin. The cells were then exposed to acivicin at the indicated concentrations for increasing periods of time (2 to 96 hr). Following drug twice and incubated for 72 hr in fresh medium containing the nucleosides treatment, the cells were washed twice, and fresh medium was added. Incubation and dipyridamole as shown. Cells were harvested after a 1- to 2-hr was continued for a total of 96 hr for all conditions. The data are expressed as the exposure to a Ca2+ and Mg2* free dispersion medium. Cells excluding percentage of control cell number present at the end of 96 hr. trypan blue were counted using a hemocytometer. Measurement of Nucleoside Triphosphate Pools. Nucleoside tri- 200r UTP phosphate pool extractions were carried out on duplicate flasks in parallel with the cell growth studies. VACO 5 cells (2.5 to 12 x 106) were collected by centrifugation (10 min, 200 x g), the medium was removed, and the cells were resuspended in 1 ml of cold phosphate-buffered saline. The suspension was transferred to a 1.5-ml microfuge tube and centrifugea (30 sec, 11,500 rpm). The supernatant was removed, and the cell pellet was extracted in 0.1 ml of 0.5 M HCIO4 for 10 min at 4°. The extract was neutralized with an equal volume of 0.5 M Alamine in Freon (12). The neutralized samples were stored at -20° until analyzed 1 I 10 1 I 10 I 1 10 I I 10 by high-pressure liquid chromatography. Chromatography of the samples ACIVICIN(pg/ml) was performed on a system consisting of a Spectra-Physics 8700 solvent Chart 2. Effects of acivicin on ribonucleotide triphosphate pools in VACO 5 delivery system, a Whatman Partisil 10/25 SAX anion-exchange column cells.
Load more

Recommended publications
  • P2X7 Receptor Suppression Preserves Blood-Brain Barrier
    www.nature.com/scientificreports OPEN P2X7 Receptor Suppression Preserves Blood-Brain Barrier through Inhibiting RhoA Activation Received: 15 November 2015 Accepted: 03 March 2016 after Experimental Intracerebral Published: 16 March 2016 Hemorrhage in Rats Hengli Zhao1, Xuan Zhang1, Zhiqiang Dai1, Yang Feng1, Qiang Li1, John H. Zhang2, Xin Liu1, Yujie Chen1 & Hua Feng1 Blockading P2X7 receptor(P2X7R) provides neuroprotection toward various neurological disorders, including stroke, traumatic brain injury, and subarachnoid hemorrhage. However, whether and how P2X7 receptor suppression protects blood-brain barrier(BBB) after intracerebral hemorrhage(ICH) remains unexplored. In present study, intrastriatal autologous-blood injection was used to mimic ICH in rats. Selective P2X7R inhibitor A438079, P2X7R agonist BzATP, and P2X7R siRNA were administrated to evaluate the effects of P2X7R suppression. Selective RhoA inhibitor C3 transferase was administered to clarify the involvement of RhoA. Post-assessments, including neurological deficits, Fluoro-Jade C staining, brain edema, Evans blue extravasation and fluorescence, western blot, RhoA activity assay and immunohistochemistry were performed. Then the key results were verified in collagenase induced ICH model. We found that endogenous P2X7R increased at 3 hrs after ICH with peak at 24 hrs, then returned to normal at 72 hrs after ICH. Enhanced immunoreactivity was observed on the neurovascular structure around hematoma at 24 hrs after ICH, along with perivascular astrocytes and endothelial cells. Both A438079 and P2X7R siRNA alleviated neurological deficits, brain edema, and BBB disruption after ICH, in association with RhoA activation and down-regulated endothelial junction proteins. However, BzATP abolished those effects. In addition, C3 transferase reduced brain injury and increased endothelial junction proteins’ expression after ICH.
    [Show full text]
  • Biochemical Differences Among Four Inosinate Dehydrogenase Inhibitors
    [CANCER RESEARCH 45.5512-5520, November 1985] Biochemical Differences among Four Inosinate Dehydrogenase Inhibitors, Mycophenolic Acid, Ribavirin, Tiazofurin, and Selenazofurin, Studied in Mouse Lymphoma Cell Culture1 Huey-Jane Lee, Katarzyna Pawlak, Binh T. Nguyen, Roland K. Robins, and Wolfgang Sadee2 Department of Pharmaceutical Chemistry, School of Pharmacy, University of California, San Francisco, California 94143 [H-J. L, K. P., B. T. N., W. S.], and Cancer Research Center, Department of Chemistry, Brigham Young University, Provo, Utah 84602 [R. K. R.J ABSTRACT 1.2.1.14) catalyzes the conversion of IMP to xanthylate, and it represents a key enzyme in the biosynthesis of guanine nucleo- The mechanism of the cellular toxicity of four ¡nosinatedehy- tides. The activity of IMP dehydrogenase is positively linked to drogenase (IMP-DH) inhibitors with different antitumor and anti cellular transformation and tumor progression; therefore, this viral pharmacological profiles was investigated in mouse lym- enzyme represents a promising target of cancer chemotherapy phoma (S-49) cell culture. Drug effects on cell growth, nucleotide (1-3). Inhibition of IMP dehydrogenase results in the depletion pools, and ÒNA and RNA synthesis were measured in the of cellular guanine nucleotides by blocking their de novo synthe presence and absence of guanine salvage supplies. Both guanine and guanosine were capable of bypassing the IMP-DH block, sis (4). Guanine nucleotides are required as substrates, activa while they also demonstrated some growth-inhibitory
    [Show full text]
  • 2'-Deoxyguanosine Toxicity for B and Mature T Lymphoid Cell Lines Is Mediated by Guanine Ribonucleotide Accumulation
    2'-deoxyguanosine toxicity for B and mature T lymphoid cell lines is mediated by guanine ribonucleotide accumulation. Y Sidi, B S Mitchell J Clin Invest. 1984;74(5):1640-1648. https://doi.org/10.1172/JCI111580. Research Article Inherited deficiency of the enzyme purine nucleoside phosphorylase (PNP) results in selective and severe T lymphocyte depletion which is mediated by its substrate, 2'-deoxyguanosine. This observation provides a rationale for the use of PNP inhibitors as selective T cell immunosuppressive agents. We have studied the relative effects of the PNP inhibitor 8- aminoguanosine on the metabolism and growth of lymphoid cell lines of T and B cell origin. We have found that 2'- deoxyguanosine toxicity for T lymphoblasts is markedly potentiated by 8-aminoguanosine and is mediated by the accumulation of deoxyguanosine triphosphate. In contrast, the growth of T4+ mature T cell lines and B lymphoblast cell lines is inhibited by somewhat higher concentrations of 2'-deoxyguanosine (ID50 20 and 18 microM, respectively) in the presence of 8-aminoguanosine without an increase in deoxyguanosine triphosphate levels. Cytotoxicity correlates instead with a three- to fivefold increase in guanosine triphosphate (GTP) levels after 24 h. Accumulation of GTP and growth inhibition also result from exposure to guanosine, but not to guanine at equimolar concentrations. B lymphoblasts which are deficient in the purine salvage enzyme hypoxanthine guanine phosphoribosyltransferase are completely resistant to 2'-deoxyguanosine or guanosine concentrations up to 800 microM and do not demonstrate an increase in GTP levels. Growth inhibition and GTP accumulation are prevented by hypoxanthine or adenine, but not by 2'-deoxycytidine.
    [Show full text]
  • We Have Previously Reported' the Isolation of Guanosine Diphosphate
    VOL. 48, 1962 BIOCHEMISTRY: HEATH AND ELBEIN 1209 9 Ramel, A., E. Stellwagen, and H. K. Schachman, Federation Proc., 20, 387 (1961). 10 Markus, G., A. L. Grossberg, and D. Pressman, Arch. Biochem. Biophys., 96, 63 (1962). "1 For preparation of anti-Xp antisera, see Nisonoff, A., and D. Pressman, J. Immunol., 80, 417 (1958) and idem., 83, 138 (1959). 12 For preparation of anti-Ap antisera, see Grossberg, A. L., and D. Pressman, J. Am. Chem. Soc., 82, 5478 (1960). 13 For preparation of anti-Rp antisera, see Pressman, D. and L. A. Sternberger, J. Immunol., 66, 609 (1951), and Grossberg, A. L., G. Radzimski, and D. Pressman, Biochemistry, 1, 391 (1962). 14 Smithies, O., Biochem. J., 71, 585 (1959). 15 Poulik, M. D., Biochim. et Biophysica Acta., 44, 390 (1960). 16 Edelman, G. M., and M. D. Poulik, J. Exp. Med., 113, 861 (1961). 17 Breinl, F., and F. Haurowitz, Z. Physiol. Chem., 192, 45 (1930). 18 Pauling, L., J. Am. Chem. Soc., 62, 2643 (1940). 19 Pressman, D., and 0. Roholt, these PROCEEDINGS, 47, 1606 (1961). THE ENZYMATIC SYNTHESIS OF GUANOSINE DIPHOSPHATE COLITOSE BY A MUTANT STRAIN OF ESCHERICHIA COLI* BY EDWARD C. HEATHt AND ALAN D. ELBEINT RACKHAM ARTHRITIS RESEARCH UNIT AND DEPARTMENT OF BACTERIOLOGY, THE UNIVERSITY OF MICHIGAN Communicated by J. L. Oncley, May 10, 1962 We have previously reported' the isolation of guanosine diphosphate colitose (GDP-colitose* GDP-3,6-dideoxy-L-galactose) from Escherichia coli 0111-B4; only 2.5 umoles of this sugar nucleotide were isolated from 1 kilogram of cells. Studies on the biosynthesis of colitose with extracts of this organism indicated that GDP-mannose was a precursor;2 however, the enzymatically formed colitose was isolated from a high-molecular weight substance and attempts to isolate the sus- pected intermediate, GDP-colitose, were unsuccessful.
    [Show full text]
  • Synthesis and Biological Evaluation of Purine and Pyrimidine Based Ligands for the A3 and the P2Y2 Purinergic Receptors
    Synthesis and Biological Evaluation of Purine and Pyrimidine Based Ligands for the A3 and the P2Y2 Purinergic Receptors Apr. Liesbet Cosyn Thesis submitted to the Faculty of Pharmaceutical Sciences to obtain the degree of Doctor in Pharmaceutical Sciences Promoter Prof. dr. apr. Serge Van Calenbergh Academic year 2007-2008 TABLE OF CONTENTS 1 INTRODUCTION ................................................................................................. 3 1.1 Purinergic Receptors ................................................................................. 3 1.2 Adenosine Analogues and the Adenosine A3 Receptor ......................... 4 1.2.1 Adenosine................................................................................................. 4 1.2.2 The Adenosine Receptors: G-protein-Coupled Receptors........................ 7 1.2.3 Adenosine Receptor Subtypes and Their Signalling............................... 10 1.2.4 The Adenosine A3 Receptor ................................................................... 12 1.2.4.1 Adenosine A3 Receptor Agonists ................................................. 12 1.2.4.2 Adenosine A3 Receptor Antagonists ............................................ 16 1.2.4.3 Allosteric Modulation.................................................................... 21 1.2.4.4 Molecular Modeling of the Adenosine A3 Receptor...................... 22 1.2.4.5 The Neoceptor concept................................................................ 23 1.2.4.6 Therapeutic Potential of A3AR Agonists......................................
    [Show full text]
  • Reversibility Ofthe Pyrophosphoryl Transfer from ATP to GTP By
    Proc. Nat. Acad. Sci. USA Vol. 71, No. 9, pp. 3470-3473, September 1974 Reversibility of the Pyrophosphoryl Transfer from ATP to GTP by Escherichia coli Stringent Factor (guanosine 5'-diphosphate-3'-diphosphate/guanosine 5'-triphosphate-3'-diphosphate/relaxed control/ribosomes) JOSE SY The Rockefeller University, New York, N.Y. 10021 Communicated by Fritz Lipmann, July 1, 1974 ABSTRACT The stringent factor-catalyzed, ribosome- was incubated for 60 min at 300 in a 1W0-1 mixture contain- dependent synthesis of guanosine polyplosphates is ing: 50 mM Tris OAc, pH 8.1; 4 mM dithiothreitol; 20 mM found to be reversible. The reverse reaction specifically requires 5'-AMP as the pyrophosphoryl acceptor, and Mg(OAc)2; 5 mM ATP; 10 ,ug of poly(A, U, G); 27 pgof tRNA; guanosine 5'-triphosphate-3'-diphospbate is preferentially 90',g of ethanol-washed ribosomes; and 2 p&g of fraction II utilized as the pyrophosphoryl donor. The primary prod- stringent factor. By minimizing GTPase activity with the ucts of the reaction are GTP and ANP. The reverse reaction use of high Mg++ concentration and ethanol-washed ribo- is strongly inhibited by the antibiotics thiostrepton and a ob- tetracycline, and b' A P and,1-y-pnethylene-adenosixie- somes with a minimal time of incubation, product is triphosphate, but not by ADP, GTP, and GIDP. The reverse tained that is more than 95% pppGpp. After incubation, 1 Al reaction occurs under conditions for nonribosomal syn- of 88% HCOOH was added and the resulting precipitate dis- thesis. The ove'rill reaction for stringent factor-catalyzed carded.
    [Show full text]
  • United States Patent Office Patented Oct
    3,346,562 United States Patent Office Patented Oct. 10, 1967 2 3,346,562 cg METHOD FOR THE PRODUCTION OF PO-CE Base RBONUCLEOSDE-5'-PHOSPHATE / O Mikio Honjo, Takatsuki, and Ryuji Maremoto, Minoo, Cl EO Japan, assignors to Takeda Chemical industries, Ltd., Osaka, Japan No Drawing. Filed May 31, 1966, Ser. No. 553,718 Claims priority, application Japan, May 29, 1965, R. X R. 40/31,814 9 Claims. (Cl. 260-21.5) HO. O. BIO O 10 N1 N1 This invention is concerned with a method for the pro Po-H, Base Po-H, Base duction of ribonucleoside-5'-phosphate. EIO k" wE+ EO k". Ribonucleoside-5'-phosphate is very useful as condi H HO - ment for food and also in the pharmaceutical industry, O O OH OH and has been chemically produced by at first protecting 15 X the hydroxyl groups at the 2'- and 3'-positions of its ribose R1 R2 moiety with acyl or isopropylidene groups and then phos phorylating the 5'-hydroxyl group of the thus-protected RN compound with pentavalent phosphorus compound such C=O: aliphatic ketone or aromatic aldehyde as phosphorus pentachloride, phosphorus oxychloride, 20 R?2 etc., followed by removing the protecting groups. As "ribonucleoside' in the present method there are However, this hitherto-known method requires a long used those containing purine base such as adenosine, time (about 7 to about 30 hours) for completing the pro inosine, etc. or those containing pyrimidine base such as tection and phosphorylation, and therefore is not desirable uridine, cytidine, etc. As the aliphatic ketone having 3 from an industrial viewpoint.
    [Show full text]
  • Inosine in Biology and Disease
    G C A T T A C G G C A T genes Review Inosine in Biology and Disease Sundaramoorthy Srinivasan 1, Adrian Gabriel Torres 1 and Lluís Ribas de Pouplana 1,2,* 1 Institute for Research in Biomedicine, Barcelona Institute of Science and Technology, 08028 Barcelona, Catalonia, Spain; [email protected] (S.S.); [email protected] (A.G.T.) 2 Catalan Institution for Research and Advanced Studies, 08010 Barcelona, Catalonia, Spain * Correspondence: [email protected]; Tel.: +34-934034868; Fax: +34-934034870 Abstract: The nucleoside inosine plays an important role in purine biosynthesis, gene translation, and modulation of the fate of RNAs. The editing of adenosine to inosine is a widespread post- transcriptional modification in transfer RNAs (tRNAs) and messenger RNAs (mRNAs). At the wobble position of tRNA anticodons, inosine profoundly modifies codon recognition, while in mRNA, inosines can modify the sequence of the translated polypeptide or modulate the stability, localization, and splicing of transcripts. Inosine is also found in non-coding and exogenous RNAs, where it plays key structural and functional roles. In addition, molecular inosine is an important secondary metabolite in purine metabolism that also acts as a molecular messenger in cell signaling pathways. Here, we review the functional roles of inosine in biology and their connections to human health. Keywords: inosine; deamination; adenosine deaminase acting on RNAs; RNA modification; translation Citation: Srinivasan, S.; Torres, A.G.; Ribas de Pouplana, L. Inosine in 1. Introduction Biology and Disease. Genes 2021, 12, 600. https://doi.org/10.3390/ Inosine was one of the first nucleobase modifications discovered in nucleic acids, genes12040600 having been identified in 1965 as a component of the first sequenced transfer RNA (tRNA), tRNAAla [1].
    [Show full text]
  • Questions with Answers- Nucleotides & Nucleic Acids A. the Components
    Questions with Answers- Nucleotides & Nucleic Acids A. The components and structures of common nucleotides are compared. (Questions 1-5) 1._____ Which structural feature is shared by both uracil and thymine? a) Both contain two keto groups. b) Both contain one methyl group. c) Both contain a five-membered ring. d) Both contain three nitrogen atoms. 2._____ Which component is found in both adenosine and deoxycytidine? a) Both contain a pyranose. b) Both contain a 1,1’-N-glycosidic bond. c) Both contain a pyrimidine. d) Both contain a 3’-OH group. 3._____ Which property is shared by both GDP and AMP? a) Both contain the same charge at neutral pH. b) Both contain the same number of phosphate groups. c) Both contain the same purine. d) Both contain the same furanose. 4._____ Which characteristic is shared by purines and pyrimidines? a) Both contain two heterocyclic rings with aromatic character. b) Both can form multiple non-covalent hydrogen bonds. c) Both exist in planar configurations with a hemiacetal linkage. d) Both exist as neutral zwitterions under cellular conditions. 5._____ Which property is found in nucleosides and nucleotides? a) Both contain a nitrogenous base, a pentose, and at least one phosphate group. b) Both contain a covalent phosphodister bond that is broken in strong acid. c) Both contain an anomeric carbon atom that is part of a β-N-glycosidic bond. d) Both contain an aldose with hydroxyl groups that can tautomerize. ___________________________________________________________________________ B. The structures of nucleotides and their components are studied. (Questions 6-10) 6._____ Which characteristic is shared by both adenine and cytosine? a) Both contain one methyl group.
    [Show full text]
  • Central Nervous System Dysfunction and Erythrocyte Guanosine Triphosphate Depletion in Purine Nucleoside Phosphorylase Deficiency
    Arch Dis Child: first published as 10.1136/adc.62.4.385 on 1 April 1987. Downloaded from Archives of Disease in Childhood, 1987, 62, 385-391 Central nervous system dysfunction and erythrocyte guanosine triphosphate depletion in purine nucleoside phosphorylase deficiency H A SIMMONDS, L D FAIRBANKS, G S MORRIS, G MORGAN, A R WATSON, P TIMMS, AND B SINGH Purine Laboratory, Guy's Hospital, London, Department of Immunology, Institute of Child Health, London, Department of Paediatrics, City Hospital, Nottingham, Department of Paediatrics and Chemical Pathology, National Guard King Khalid Hospital, Jeddah, Saudi Arabia SUMMARY Developmental retardation was a prominent clinical feature in six infants from three kindreds deficient in the enzyme purine nucleoside phosphorylase (PNP) and was present before development of T cell immunodeficiency. Guanosine triphosphate (GTP) depletion was noted in the erythrocytes of all surviving homozygotes and was of equivalent magnitude to that found in the Lesch-Nyhan syndrome (complete hypoxanthine-guanine phosphoribosyltransferase (HGPRT) deficiency). The similarity between the neurological complications in both disorders that the two major clinical consequences of complete PNP deficiency have differing indicates copyright. aetiologies: (1) neurological effects resulting from deficiency of the PNP enzyme products, which are the substrates for HGPRT, leading to functional deficiency of this enzyme. (2) immunodeficiency caused by accumulation of the PNP enzyme substrates, one of which, deoxyguanosine, is toxic to T cells. These studies show the need to consider PNP deficiency (suggested by the finding of hypouricaemia) in patients with neurological dysfunction, as well as in T cell immunodeficiency. http://adc.bmj.com/ They suggest an important role for GTP in normal central nervous system function.
    [Show full text]
  • High-Throughput Profiling of Nucleotides and Nucleotide Sugars
    Journal of Biotechnology 229 (2016) 3–12 Contents lists available at ScienceDirect Journal of Biotechnology j ournal homepage: www.elsevier.com/locate/jbiotec High-throughput profiling of nucleotides and nucleotide sugars to evaluate their impact on antibody N-glycosylation a,1 b,1 a c Thomas K. Villiger , Robert F. Steinhoff , Marija Ivarsson , Thomas Solacroup , c c b b b Matthieu Stettler , Hervé Broly , Jasmin Krismer , Martin Pabst , Renato Zenobi , a a,d,∗ Massimo Morbidelli , Miroslav Soos a Institute for Chemical and Bioengineering, Department of Chemistry and Applied Biosciences, ETH Zurich, CH- 8093 Zurich, Switzerland b Laboratory of Organic Chemistry, Department of Chemistry and Applied Biosciences, ETH Zurich, CH-8093 Zurich, Switzerland c Merck Serono SA, Corsier-sur-Vevey, Biotech Process Sciences, ZI B, CH-1809 Fenil-sur-Corsier, Switzerland d Department of Chemical Engineering, University of Chemistry and Technology, Technicka 5, 166 28 Prague, Czech Republic a r t i c l e i n f o a b s t r a c t Article history: Recent advances in miniaturized cell culture systems have facilitated the screening of media additives on Received 5 October 2015 productivity and protein quality attributes of mammalian cell cultures. However, intracellular compo- Received in revised form 16 April 2016 nents are not routinely measured due to the limited throughput of available analytical techniques. In this Accepted 20 April 2016 work, time profiling of intracellular nucleotides and nucleotide sugars of CHO-S cell fed-batch processes Available online 27 April 2016 in a micro-scale bioreactor system was carried out using a recently developed high-throughput method based on matrix-assisted laser desorption/ionization (MALDI) time-of-flight mass spectrometry (TOF- Keywords: MS).
    [Show full text]
  • Effects of Allopurinol and Oxipurinol on Purine Synthesis in Cultured Human Cells
    Effects of allopurinol and oxipurinol on purine synthesis in cultured human cells William N. Kelley, James B. Wyngaarden J Clin Invest. 1970;49(3):602-609. https://doi.org/10.1172/JCI106271. Research Article In the present study we have examined the effects of allopurinol and oxipurinol on thed e novo synthesis of purines in cultured human fibroblasts. Allopurinol inhibits de novo purine synthesis in the absence of xanthine oxidase. Inhibition at lower concentrations of the drug requires the presence of hypoxanthine-guanine phosphoribosyltransferase as it does in vivo. Although this suggests that the inhibitory effect of allopurinol at least at the lower concentrations tested is a consequence of its conversion to the ribonucleotide form in human cells, the nucleotide derivative could not be demonstrated. Several possible indirect consequences of such a conversion were also sought. There was no evidence that allopurinol was further utilized in the synthesis of nucleic acids in these cultured human cells and no effect of either allopurinol or oxipurinol on the long-term survival of human cells in vitro could be demonstrated. At higher concentrations, both allopurinol and oxipurinol inhibit the early steps ofd e novo purine synthesis in the absence of either xanthine oxidase or hypoxanthine-guanine phosphoribosyltransferase. This indicates that at higher drug concentrations, inhibition is occurring by some mechanism other than those previously postulated. Find the latest version: https://jci.me/106271/pdf Effects of Allopurinol and Oxipurinol on Purine Synthesis in Cultured Human Cells WILLIAM N. KELLEY and JAMES B. WYNGAARDEN From the Division of Metabolic and Genetic Diseases, Departments of Medicine and Biochemistry, Duke University Medical Center, Durham, North Carolina 27706 A B S TR A C T In the present study we have examined the de novo synthesis of purines in many patients.
    [Show full text]